Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has suffered a setback in its efforts to combine two HIV drugs into one convenient, once-daily tablet. The company is trying to combine its own Truvada, with Bristol-Myers Squibb's Sustiva.
Subscribe to our email newsletter
Tests have shown that the company’s second attempt at finding an effective formulation that will combine the two drugs is still not as effective as taking both drugs separately. Gilead’s shares dropped by over 4% after the announcement of the failed formulation, although the company has said that it is proceeding with the evaluation of up to three new formulations of the compound drug.
Gilead and Bristol-Myers Squibb announced the establishment of a US joint venture to co-formulate the drugs in a fixed-dose regimen, in 2004. The companies now anticipate filing a new drug application with the FDA in the first half of 2006, if they can find a successful formulation.
If approved, the new product would be the first complete Highly Active Antiretroviral Therapy (HAART) treatment regimen for HIV available in a fixed-dose combination taken once daily.